Trial Profile
A phase II, randomised, partially-blinded, cross over study to evaluate the systemic effect of two doses of the SMB BUDESONIDE-SALMETEROL DPI fixed-dose combination capsule (300/25 microg BID and 150/25 microg BID) delivered by the AXAHALER versus PULMICORT TURBOHALER 400microg BID and SEREVENT DISKUS 50microg BID versus placebo in mild persistent asthmatic patients.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Jun 2011
Price :
$35
*
At a glance
- Drugs Budesonide/salmeterol (Primary) ; Budesonide; Salmeterol
- Indications Asthma
- Focus Adverse reactions; Pharmacodynamics
- 24 Jun 2011 New trial record